(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

COMPOSTOS DE ALVO DE RECEPTOR DE HORMÔNIO NUCLEAR ANTICÂNCER

ArquivadaInvention PatentPCT · US2019032295 Official document available

Application data

Number

112020023136

Type

Invention Patent

Filing

05/14/2019

Publication

02/09/2021

PCT

US2019032295

Patent grant document available

We have the complete official document for this filing, as published by INPI.

Access the document

Progress at the INPI

  1. Filing05/14/19
  2. Publication02/09/21
  3. Abandoned
  4. Allowance
  5. Grant
  6. In force

The application was abandoned: the INPI technical office action was not answered in time (art. 36 of the Brazilian IP Act). The technology is in the public domain in Brazil.

Talk to a specialist

Latest action published by the INPI: 12/03/2024. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

NUVATION BIO INC.

US

See this company's full portfolio

Inventors

A. N. (pessoa física)

IN

A. B. (pessoa física)

IN

D. H. (pessoa física)

US

J. K. (pessoa física)

US

J. C. (pessoa física)

US

S. C. (pessoa física)

US

S. P. (pessoa física)

US

Technical data

Priority claims

US

62/671,382 · 05/14/2018

Abstract

"COMPOSTOS DE ALVO DE RECEPTOR DE HORMÔNIO NUCLEAR ANTICÂNCER".A presente invenção refere-se a compostos anticâncer derivados de ligantes do receptor de esteroide nuclear, a produtos contendo os mesmos, bem como a métodos de seu uso e preparação.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Arquivamento - Art. 36 §1° da LPI

#11.2

12/03/2024

RPI 2813

Parecer de pré-exame

#6.23

08/13/2024

RPI 2797

Adição na publicação

#15.35

12/14/2021

RPI 2658

Notificação de entrada na fase nacional - PCT

#1.3

02/09/2021

RPI 2614

Alteração de dados cadastrais

#1.1

11/24/2020

RPI 2603

Related

Same category

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.